The role of vitamin D in pre-eclampsia: a systematic review

Juhi M. Purswani, Pooja Gala, Pratibha Dwarkanath, Heather M. Larkin, Anura Kurpad and Saurabh Mehta

Abstract

Background: The etiology of pre-eclampsia (PE) is not yet fully understood, though current literature indicates an upregulation of inflammatory mediators produced by the placenta as a potential causal mechanism. Vitamin D is known to have anti-inflammatory properties and there is evidence of an inverse relationship between dietary calcium intake and the incidence of PE. Evidence of the role of vitamin D status and supplementation in the etiology and prevention of PE is reviewed in this article along with identification of research gaps to inform future studies.

Methods: We conducted a structured literature search using MEDLINE electronic databases to identify published studies until February 2015. These sources were retrieved, collected, indexed, and assessed for availability of pregnancy-related data on PE and vitamin D.

Results: Several case-control studies and cross-sectional studies have shown an association between vitamin D status and PE, although evidence has been inconsistent. Clinical trials to date have been unable to show an independent effect of vitamin D supplementation in preventing PE.

Conclusions: The included clinical trials do not show an independent effect of vitamin D supplementation in preventing PE; however, issues with dose, timing, and duration of supplementation have not been completely addressed.

Keywords: Vitamin D, Pregnancy, Pregnancy-induced hypertension, Pre-eclampsia, Endothelial function

Background

Each day, 830 women die from preventable pregnancy-related causes; low- and middle-income countries bear the greatest burden of disease [1]. Hypertensive disorders of pregnancy, including gestational hypertension, pre-eclampsia (PE), and eclampsia, are among the major complications that account for approximately 14% of maternal mortality [1, 2]. Pregnancy induced hypertension, defined as blood pressure greater than 140/90 mmHg on two consecutive occasions ≥6 h apart occurring after 20 weeks of pregnancy, complicates approximately 10% of all pregnancies worldwide. Pre-eclampsia (PE) is hypertension and proteinuria (protein in urine ≥0.3 g/24 h (1+ dipstick) on two occasions ≥6 h apart) or edema [3, 4]. It is a major cause of maternal and perinatal morbidity and mortality and complicates 2% to 8% of pregnancies [3, 5]. Early onset severe PE (EOSPE) is diagnosed between 20 to 34 weeks gestation and is associated with a 20-fold increased risk for maternal mortality compared to PE after 34 weeks gestation [6] called late onset severe PE (LOSPE). Pregnant women who show signs of pregnancy induced hypertension or PE can develop eclampsia, which is the occurrence of unexplained seizures [7].

The complications of PE include eclampsia, disseminated intravascular coagulation and the HELLP syndrome (hemolytic anemia, elevated liver enzymes, and low platelets [5]). Risks to the fetus include intrauterine growth restriction (IUGR) and fetal death [8]. Pathognomonic features shared by PE and IUGR include abnormal placental implantation and reduced trophoblastic invasion [9]. Similarly, EOSPE and LOSPE are associated with fetal death, perinatal death, and severe neonatal morbidity. For example, in an analysis of 456,668 singleton births in Washington state, EOSPE was associated

*Correspondence: smehta@cornell.edu
1Division of Nutritional Sciences, Cornell University, 314 Savage Hall, Ithaca, NY 14853, USA
2St. John’s Research Institute, Bangalore, Karnataka, India
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
with high risk of fetal death; the adjusted odds ratio (aOR) was 5.8 (95% Confidence Interval (CI): 4.0–8.3 vs. 1.3 for LOSPE (95% CI: 0.8–2.0). The aOR for perinatal death/severe neonatal morbidity was 16.4 (95% CI: 14.5–18.6) in EOSPE and 2.0 (95% CI: 1.8–2.3) in LOSPE [10]. Women with a history of PE also have a higher risk of cardiovascular disease later in life [11, 12].

For years, PE has been hypothesized to be a two-stage disorder [13]. In the first stage, placental perfusion is reduced resulting in defective placental implantation. In the second stage, reduced vasculatization at the placental site activates a maternal inflammatory response. This leads to generalized endothelial dysfunction and the release of excessive anti-angiogenic factors into the maternal bloodstream resulting in hypertension. In PE, higher amounts of soluble fms-like tyrosine kinase 1 (sFLT-1) are produced in the placenta. sFLT-1 competitively binds to placental growth factor (PIGF) and vascular endothelial growth factor (VEGF) creating an angiogenically imbalanced vascular environment that prevents proper endothelial preservation [14, 15]. More recently, a modified version of the two-stage hypothesis has been developed, which proposes that maternal constitutional factors (genetics, obesity, diet, co-morbid disease) in combination with normal inflammatory changes in pregnancy can lead directly to endothelial dysfunction with or without the contribution of reduced placental perfusion [16, 17].

Hypovitaminosis D has been associated with PE [18]. While the pathogenesis of PE involves a number of biological processes, there are several hypotheses to suggest how vitamin D levels may affect these processes (Table 1). These include vitamin D’s role in modulating pro-inflammatory responses and decreasing oxidative stress in PE, promoting angiogenesis through VEGF and gene modulation, and decreasing blood pressure through the renin-angiotensin system (RAS) [19–25].

**Biological plausibility of the role of vitamin D in PE**

Vitamin D₃, or cholecalciferol, is formed endogenously when 7-dehydrocholesterol in keratinocytes is converted to a seco-steroid pro-hormone upon irradiation by UV-B light. This is followed by two successive hydroxylations - first at the 25 position to form 25-hydroxyvitamin D [25(OH)D], which occurs in the liver, and second to form the active hormonal metabolite 1,25-dihydroxyvitamin D [1,25(OH)₂D], also called calcitriol, which is largely carried out in the kidney. Calcitriol binds to its cognate nuclear receptor and modulates gene expression mainly related to calcium absorption in the intestine. Calcitriol can also modulate immune function through a rapid action pathway by binding to receptors on the plasma membrane when the active hormone is synthesized in situ by several extra-renal tissues, namely macrophages, endothelium, cells in the prostate, and keratinocytes, as all of them express the vitamin D receptor [25].

Vitamin D status is determined by the measurement of its circulating form, 25-hydroxyvitamin D [25(OH)D] [26]. Vitamin D is considered adequate when 25(OH)D levels are above 50 nmol/L, as defined by the Institute of Medicine. A level between 30 and 50 nmol/L is considered insufficient, and less than 30 nmol/L, deficient [27].

In the past decade, maternal vitamin D insufficiency and deficiency have increasingly been recognized as a public health concern. Insufficiency has been linked to adverse maternal and fetal outcomes, including poor fetal and infant bone mineralization [28, 29], hypocalcemia and rickets in neonates [30]. A number of prospective observational studies have shown a high prevalence of hypovitaminosis D during pregnancy in developing and developed countries [31]. Risk factors that affect vitamin D status include season, time of the day, latitude, clothing and skin color [32]. Vitamin D deficiency is commonly found among pregnant women in various ethnic populations [33–37]. African American women of reproductive age have been found to be at particularly high risk for vitamin D deficiency in the United States [18]. Clothing with minimal skin exposure [38, 39], increased urbanization, skin pigmentation [40], and vegetarian diets [35] are all believed to have contributed to a vitamin D deficiency epidemic worldwide.

During the course of pregnancy, evidence from observational studies shows divergent data on the concentration of serum 25(OH)D levels in different trimesters of pregnancy, with either decline [41], increase [42], or absence of change in vitamin D levels with progression [43, 44].

**Table 1** Summary of Effects of increased vitamin D on the pathogenesis of pre-eclampsia (PE)

| Stage of PE | Characteristic of PE | ↑ Vitamin D |
|-------------|----------------------|------------|
| Stage 1     | Inflammation-linked abnormal placentation implantation | ↓ Predisposition to pro-inflammatory response [20] |
|             |                      | ↑ Regulation of genes associated with placental invasion and normal implantation [20] |
| Stage 2     | Vascular Endothelial dysfunction | ↑ Vascular structure, elasticity and intima-media thickness |
|             |                      | ↓ Blood pressure (regulation of renin-angiotensin system) [63] |
|             |                      | ↓ Oxidative stress [24] |
|             | Proteinuria mediated by renal vascular endothelial growth factor (VEGF) | ↑ Vascular smooth muscle cell proliferation by increasing VEGF gene transcription [19] |
It is plausible that a deficiency in vitamin D and its downstream products can play a role in the etiology of PE. Human decidual cells at the fetal-maternal interface synthesize active 1,25(OH)\(_2\)D via 1alpha-hydroxylase (CYP27B1) [45–47]. Syncytiotrophoblasts responsible for invading the uterine wall for fetal implantation also express active CYP27B1, in addition to vitamin D receptor (VDR), vitamin D binding protein (VDBP), 25-hydroxylase, and 24-hydroxylase. Metabolic homeostasis of these proteins has been shown to be significantly altered in placental tissue from pregnancies with PE compared to controls [48, 49]. In a study in which human extravillous trophoblasts were treated in vitro with 1,25(OH)\(_2\)D or 25(OH)D, there was a significant increase in EVT invasion into cell cultures when compared with untreated controls (\(p < 0.01\)) [47]. Additionally, vitamin D likely plays a key role in the pathology of pre-eclamptic conditions by affecting blood pressure through calcium homeostasis and/or modulating inflammation and immunity, which are examined further in this review.

**Role of vitamin D as an anti-inflammatory agent and immune modulator**

Vitamin D is thought to play a significant role in PE as an immune modulator [20, 50]. It may help mount an appropriate maternal immune response to the placenta preventing the release of anti-angiogenic factors into the bloodstream and modulating hypertension [50]. For example, 1,25(OH)\(_2\)D suppresses T cell receptor-induced cytokines expression and interleukin-6 secretion [50]. 1,25(OH)\(_2\)D is also suspected to be involved in the regulation of IL-10, which has an inhibitory effect on pro-inflammatory cytokines expression in the human placenta. For example, 1,25(OH)\(_2\)D may undertake the anti-inflammatory effects of IL-10 by itself to inhibit expression of placental Th1-cytokines, which are increased in PE. Barerra et al. showed that calcitriol down-regulates IL-10 under normal, natural and experimental inflammatory conditions in cultured human trophoblasts [54]. Calcitriol has also been shown to decrease TNF-a and IL-6 expression [52].

In addition to down-regulating the release of anti-angiogenic factors, vitamin D has been shown to promote angiogenesis in endothelial progenitor cells, by possibly increasing VEGF expression and pro-matrix metalloproteinase (pro-MMP-2) activity [55]. MMPs are implicated in the pathogenesis of vascular dysfunction associated with PE [56, 57]. There is evidence that 1,25(OH)\(_2\)D is synthesized in the vascular endothelial cells [58] and induces vascular smooth muscle cell (VSMC) proliferation [19]. Brodowski et al. showed that supplemented 1,25(OH)\(_2\)D on endothelial progenitor cells reversed endothelial dysfunction seen in preeclampsia [59]. Cardus et al. found that the effect of 1,25(OH)\(_2\)D on VSMC proliferation is mediated by increased VEGF expression, while others find no relation between vitamin D and pro-angiogenic factors [15]. There is currently not enough data to strongly support the hypothesis that impaired angiogenesis explains the association between vitamin D deficiency and PE [60].

**Role of vitamin D and blood pressure regulation**

An inverse relationship between plasma 1,25(OH)\(_2\)D and plasma renin activity has been observed. The RAS plays an important role in regulation of blood pressure. During normal pregnancy, RAS is stimulated so that there is an increase in circulating levels of renin, angiotensinogen and angiotensin II [61]. In PE, circulating serum angiotensin I, angiotensin II and aldosterone are lower compared to normotensive women, while plasma active renin levels and autoantibodies to the Angiotensin II type 1 receptor, which stimulate receptor signaling to increase systemic blood pressure, are higher [62–64]. These findings suggest a hemodynamic dysregulation in PE involving the RAS. Vitamin D metabolites may suppress renin gene transcription by a vitamin D receptor (VDR) dependent pathway [65] or reduce autoantibodies to the Angiotensin II type I receptor [64]. In one study, oral vitamin D2 (VD2, 270 IU/day) and vitamin D3 (VD3, 15 IU/day) lowered mean arterial blood pressure (mm Hg) in pregnant rats infused with autoantibodies to Angiotensin II type I receptor (VD2: 105 +/- 2, VD3: 109 +/- 2) versus rats that were infused with autoantibodies to Angiotensin II type I receptor but did not receive oral VD2 or VD3 (121 +/- 4) [64]. Studies have shown an inverse relationship between plasma 1,25(OH)\(_2\)D levels and blood pressure [66], and plasma 1,25(OH)\(_2\)D levels and essential hypertension [67]. In vitro and in vivo studies have found receptors for calcitriol in vascular smooth muscle [68] and heart muscle [69]. A study of mice found receptors for calcitriol in regions of the spinal cord and brain stem that are associated with blood pressure regulation [70].
Role of vitamin D and vitamin D receptor (VDR) in calcium homeostasis

The effects of calcium supplementation on pregnancy-induced hypertensive disorders are well characterized. A Cochrane meta-analysis of 13 randomized trials involving 15,730 women found that at least 1 g daily calcium supplementation lowers the average risk of PE by approximately half (relative risk [RR]: 0.45, 95% CI: 0.31–0.65) [71]. Low calcium levels may lead to hypertension by stimulating either the parathyroid hormone (PTH) or renin release, resulting in vasoconstriction due to increased intracellular calcium in vascular smooth muscle [72, 73]. Further calcium absorption has been found to be positively associated with serum 1,25(OH)2D concentrations in late pregnancy [74, 75]. The high concentration of this metabolite inhibits serum PTH synthesis and secretion, promoting the active intestinal absorption of calcium.

It is also observed that calcium sufficiency may occur independently of vitamin D sufficiency. In a study of female mice with a VDR null mutation and rickets, intestinal absorption of calcium and whole-body mineral content was significantly reduced compared to wild type mice before pregnancy (0.381 ± 0.026 vs. 0.529 ± 0.023, p < 0.001). During pregnancy, 1,25(OH)2D levels doubled in both groups and VDR null mice gained 158% of bone mineral content from baseline. By day 16.5 of pregnancy, intestinal calcium absorption in VDR null mice was equivalent to non-pregnant wild type mice, but did not reach levels of pregnant wild type mice [76].

Given the role of vitamin D in modulation of inflammation and immune function, placental implantation, angiogenesis and adverse birth outcomes such as low birth weight and SGA, we examined the evidence that vitamin D may play a role in the etiology and prevention of PE in this manuscript.

Methods

Search strategy

The review protocol was designed a priori to answer the question, “What are the effects of vitamin D concentrations and supplementation during pregnancy on pre-eclampsia in women?” We conducted a literature search using MEDLINE electronic databases (via PubMed) to identify published studies until February 2015. Search terms: (preeclampsia OR pre-eclampsia) AND (vitamin D OR hypovitaminosis D OR 1,25 dihydroxyvitamin D OR (vitamin D AND (supplementation OR supplement)) OR dihydroxyvitamin D OR 25 hydroxyvitamin D). The search was confined to peer-reviewed articles that were published in English and contained an abstract. Reference lists of journal articles were also screened for additional citations fitting our search criteria.

Articles were screened independently by two authors (JP and PG) for relevance based on the title and abstract. In the event that the number of RCTs returned by the search was insufficient to conduct a meta-analysis of PIH outcomes, authors planned to give a structured review of both experimental and observational studies. Considering retrospective and observational designs are more prone to bias than experimental design, results of clinical trials are presented separately and given more weight in conclusions and interpretations. An individual Risk of Bias assessment was not done given structured review design. Selected journal articles were then retrieved, collected, indexed, and assessed for availability of pregnancy-related data on PE and vitamin D by JP and PG. The inclusion criteria for this review were availability of an abstract, clinical data on vitamin D concentrations and/or supplementation in association with PIH outcomes in any global setting, and subjects that included pregnant participants aged 18 years and above without other medical co-morbidities. Studies were excluded if they were reviews, commentaries, editorials, letters, non-human studies, didn’t include maternal vitamin D measured during gestation as a primary or secondary variable, or did not include PE as a primary or secondary outcome.

Data extraction

Selected studies were read and desired data were extracted independently by two authors (JP and PG). A third author, PD cross-checked data extraction to establish 100% agreement between the two independent reviewers. The following elements were extracted for each study: Author; year of publication; country; study design; objective, methods, exposure and outcome measures, sample size and key findings. All authors reviewed the final summary of selected studies and resolved any data discrepancies through discussion. Principal summary measures included risk of PIH outcomes and change in means of continuous PIH indicators such as hypertension.

Results

The structured literature search resulted in 233 articles. 200 studies were excluded (60 reviews, 55 non-human studies, 85 studies that didn’t meet the inclusion criteria described above (Fig. 1). A total of 33 studies were extracted for further review. The reviewed studies included 3 cross-sectional studies, 20 case control studies, 2 retrospective cohort studies, 6 prospective cohort studies and 2 randomized controlled trials.

A detailed summary of the search strategy and results is presented in Fig. 1. The PRISMA Checklist for this review can be found in Additional file 1.

Evidence to support the role of vitamin D in PE

Several cohort and case control studies measuring vitamin D before the development of PE show an association
between vitamin D and PE (Tables 2 and 3). In a large cohort study of 22,057 nulliparous women, no association was found between vitamin D intake from diet alone and the incidence of PE. However, when considering total vitamin D intake (diet + supplement) of 15–20 μg/d compared to less than 5 μg/d, there was an adjusted OR of 0.76 (95% CI 0.60–0.95) for diagnosis with PE [77]. There was an adjusted OR of 0.72 (95% CI 0.58–0.92) in women with vitamin D intake of 10–15 μg/d from supplementation of vitamin D alone when compared with no supplementation. A limitation of this study was that it was unable to adjust for intake of long chain n-3 fatty acids, which correlated with vitamin D intake in a Norwegian diet. Another prospective cohort study of nulliparous women with singleton pregnancies found no significant association between vitamin D deficiency in the 1st trimester and risk for PE; however, at 24–26 weeks of gestation mean maternal 25(OH)D was significantly lower in women who developed PE compared with those who did not (p = 0.03) [60]. The adjusted OR was 3.24 for PE (95% CI:1.37–7.69) in women with 25(OH)D levels less than 50 nmol/l. Strengths of this study were that vitamin D was measured in both high and low risk women, representing a realistic clinical scenario. A retrospective cohort study showed that at entry to care (13.7 ± 5.7 weeks) there was an increased risk of PE in women with 25(OH)D levels less than 49.9 nmol/L and high parathyroid hormone (> 62 pg/mL) (aOR 2.86; 95% CI: 1.28–6.41) [78]. However, there was no association in women with vitamin D insufficiency who did not also have high PTH.

A case-cohort study of women from 12 different United States (US) sites whose vitamin D levels were measured at ≤26 weeks of gestation showed that 25(OH)D levels greater than 50 nmol/L were associated with a 40% reduction in risk for severe PE (0.65 [95% CI 0.43 to 0.98]), although there was no reduction in absolute and relative risk for the milder clinical subtypes of PE when 25(OH)D levels were greater than 50 nmol/L.
Table 2 Characteristics of included reports

| Author, Location, Year | Design            | Subjects                                                                 | Time of vitamin D measurement |
|------------------------|-------------------|---------------------------------------------------------------------------|--------------------------------|
| Cross-Sectional Studies|                   |                                                                           |                                |
| August et al., USA, 1992 [88] | Cross-sectional   | 11 – women with PE 9 – chronic HTN 12 – normotensive pregnant controls   | 3rd trimester                   |
| Fernandez-Alonzo et al., Spain, 2012 [97] | Cross-sectional | 466 – pregnant women (7 had PE)                                           | 1st trimester                   |
| Pena HR, et al. Brazil 2015 [83] | Cross-sectional  | 179 – pregnant women recruited before delivery                             | Near delivery                   |
| Case Control Studies   |                   |                                                                           |                                |
| Abedi et al., Iran, 2014 [84] | Case Control      | 59 – women with PE 59 – healthy pregnant controls                          | At delivery                     |
| Achkar et al., Canada, 2015 [81] | Case Control      | 169 – women with PE 1975 – healthy pregnant controls                       | <20 weeks gestation             |
| Anderson et al., USA, 2015 [111] | Case control      | 11 – gestational HTN (10/11 with PE)                                       | At delivery                     |
| Baker et al., 2010 [80] | Nested Case Control | 51 – developed PE 204 – healthy pregnant controls                        | 2nd trimester                   |
| Bodnar et al., USA, 2007 [18] | Nested Case Control | 55 – developed PE 219 – healthy pregnant controls                       | <22 weeks gestation             |
| Bodnar et al., USA, 2014 [79] | Case Control      | 717 – developed PE 560 mild; 157 severe 2986 – healthy pregnant controls | <26 weeks gestation             |
| Gidlof S, et al. Sweden, 2015 [112] | Nested Case Control | 39 – developed preeclampsia 120 – healthy pregnant controls                  | 12th week of gestation           |
| Halhali, Mexico, 2004 [95] | Case Control      | 10 – developed PE 40 – healthy pregnant controls                          | Median 20.7 weeks gestation     |
| Halhali et al., Mexico, 2007 [113] | Case Control      | 26 – women with PE 26 – healthy pregnant controls                          | 3rd trimester                   |
| Lechtermann C, et al. Germany, 2–14 [85] | Case Control      | 20 – women with PE 43 – healthy pregnant controls                         | At delivery                     |
| Mohaghegh et al., Iran, 2015 [89] | Case Control      | 41 – women with PE 50 – healthy pregnant controls                         | Time of labor                   |
| Powe, USA, 2010 [86] | Nested Case Control | 39 – developed PE 131 – healthy pregnant controls                      | 1st trimester                   |
| Robinson et al., USA, 2010 [25] | Case Control      | 50 – women with EOSPE 100 – healthy pregnant controls                      | 29 weeks gestation              |
| Schneuer et al., Australia, 2014 [114] | Nested Case Control | 5109 pregnant women (223 with PE and 29/223 with EOSPE)                     | 10–14 weeks gestation           |
| Singla et al., India, 2015 [87] | Case Control      | 74 – nulliparous women with PE 100 – healthy nulliparous controls          | >30 weeks gestation             |
| Ullah et al., Bangladesh, 2013 [82] | Case Control      | 33 – women with PE 79 – normal pregnancy controls                         | >20 weeks gestation             |
| Wetta et al., UK, 2013 [96] | Case Control      | 100 – women with PE 200 – healthy pregnant controls                       | 15–21 weeks gestation           |
In a nested case control study of 274 nulliparous pregnant women conducted previously by the same investigator, there was an OR of 5.0 for PE in early pregnancy (<22 weeks) when maternal 25(OH)D was less than 37.5 nmol/l after controlling for education in addition to the common confounders (95% CI: 1.7–14.1). Interestingly, it was reported that newborns of pre-eclamptic mothers were more than twice as likely to have 25(OH)D levels less than 37.5 nmol/L (aOR = 2.2, 95% CI: 1.2–4.1) than newborns of healthy controls [18]. Another nested case control study of 225 women with singleton pregnancies reported an OR of 5.41 for severe PE among women with mid-gestation vitamin D deficiency after controlling for multi-parity (95% CI: 2.02–14.52) compared to women with vitamin D levels of at least 75 nmol/L [80]. A larger Canadian case control study reported a more than twice as likely odds for PE in women with 25(OH)D less than 30 nmol/L compared to women with at least 50 nmol/L (95% CI: 1.29–3.83). There was a dose response relationship between maternal 25(OH)D and risk of PE with a threshold of effect at 50 nmol/L [81].

Observational studies which measured vitamin D status after the onset of PE [53, 82] near delivery [83] or at delivery [84, 85] suggest an inverse association with PE. A US case control study reported a trend toward increased risk of PE with 25(OH)D levels less than 15.0 nmol/L (OR = 2.5 [95% CI: 0.89-6.9]) when compared to the controls (chosen randomly from among women who remained normotensive throughout pregnancy, and did not have gestational diabetes mellitus or gave birth to SGA infants). However, this trend was not significant after adjusting for BMI and other covariates. The investigators observed a trend towards increased risk of PE at very low levels of 25(OH)D, suggesting that there may be an association at the low extreme [86]. A recent North Indian case control study of nulliparous women with PE and singleton pregnancies reported serum vitamin D to be significantly lower among PE cases vs. controls at the time of delivery (24.2 +/- 12.4 nmol/L, 36.9 +/- 16.7 nmol/L, respectively; p = 0.0001). Similar vitamin D levels were found in women with mild and severe PE [87]. Two cross-sectional studies report 25(OH)D and 1,25(OH)2D levels to be lower in women with PE in the third trimester. Although these studies find an inverse association between vitamin D levels and PE, this association may be confounded by the gestational age at serum collection. These studies are also limited in that odds ratios are not reported [83, 88].

**Table 2** Characteristics of included reports (Continued)

| Study | Design | Sample Size | Eligibility Criteria |
|-------|--------|-------------|---------------------|
| Woodham et al., USA, 2011 [15] | Nested Case Control | 41 – women with severe PE | 2nd Trimester |
| Xu et al., USA, 2014 [53] | Case Control | 100 – women with PE | ≤ 24 weeks gestation |
| Yu et al., UK, 2012 [115] | Case Control | 60 –late PE; 30 –early PE; 1000 – healthy controls | 11–13 weeks gestation |
| Alvarez-Fernandez et al., Spain, 2014 [90] | Retrospective Cohort | 257 – women attending obstetric triage with suspicion of PE | 1st Trimester and 20 weeks of gestation |
| Scholl et al., USA, 2013 [78] | Retrospective Cohort | 1141 – low income and minority pregnant women | Entry to care (mean 13.7 ± 5.7 weeks) |
| Burris et al., USA, 2014 [94] | Prospective Cohort | 1591 – pregnant women | 16.4–36.9 weeks gestation |
| Haugen et al., Norway, 2000 [77] | Prospective Cohort | 23,423 – pregnant women | Vitamin D intake at weeks 15, 22, and 30 gestation |
| Shand et al., Canada, 2010 [37] | Prospective Cohort | 221 – women at risk for PE | 10–20 weeks gestation |
| Wei et al., Canada 2012 [60] | Prospective Cohort | 697 – pregnant women receiving vitamin C and E supplementation for the prevention of PE | 12–18 weeks gestation, 24-26 weeks gestation |
| Wei, Canada, 2013 [14] | Prospective Cohort | 697 – pregnant women receiving vitamin C and E supplementation for the prevention of PE | 24–26 weeks gestation |
| Zhou, China, 2014 [116] | Prospective Cohort | 74 – women with PE | 16–20 weeks gestation |
### Table 3: Association between vitamin D and pre-eclampsia (PE) in observational studies

| Author, Location, Year | Key Findings | Results |
|-------------------------|--------------|---------|
| August et al., USA, 1992 [88] | ↓ 1,25(OH)2D in women with PE vs chronic HTN and normal women | 1,25 OH2D levels: PE: 37.8 +/- 15 pg/ml; Chronic HTN: 75 +/- 15 pg/ml (p < 0.05); normal women: 65 +/- 10 pg/ml (p < 0.05) |
| Fernandez-Alonzo et al, Spain, 2012 [97] | ↔ PE and 25(OH)D levels | 25(OH)D: <49.9 nmol/L: 28.6% (2/7 women); 49.9–74.9 nmol/L: 42.9% (3/7 women); ≥ 74.9 nmol/L: 28.6% (2/7 women) (p = 0.91) |
| Pena HR, et al. Brazil 2015 [83] | ↑ frequency of 25(OH)D deficiency <20 ng/mL in PE compared to healthy non obese controls | PE: 52.1% (25 women) Non obese controls: 14.9% (7 women) (p = 0.0006) |
| Abedi et al., Iran, 2014 [84] | ↑ vitamin D deficiency (<25.0 nmol/L) in PE cases | OR = 24.04 95% CI: 2.14–285.4 |
| Achkar et al., Canada, 2015 [81] | ↑ PE in women with 25(OH)D < 30 nmol/L vs women with at least 50 nmol/L | Adjusted OR: 2.23 95% CI: 1.29–3.83 |
| Anderson et al., USA, 2015 [111] | ↔ proportion of women with inadequate <30 ng/mL 25(OH)D levels in HTN group vs control group | 73% (HTN/PE group) vs 69% (control group) (p = 0.22) |
| Baker et al., 2010 [80] | ↑ Severe PE in women with 25(OH)D < 50 nmol/L compared to levels of at least 75 nmol/L | Adjusted OR: 5.41 95% CI: 2.02–14.52 (p = 0.001) |
| Bodnar et al., USA, 2007 [18] | ↑ PE in women with 25(OH)D < 37.5 nmol/L compared to levels of >37.5 nmol/L | Adjusted OR: 5.0 95% CI: 1.7–14.1 |
| Bodnar et al., USA, 2014 [79] | ↓ Severe PE in women with 25(OH)D ≥ 50 nmol/L compared to levels <50 nmol/L | Adjusted RR: 0.65 95% CI: 0.43–0.98 |
| Gidlof S, et al. Sweden, 2015 [112] | ↔ 25(OH)D levels in PE and healthy controls; ↔ 25(OH)D deficiency < 50 nmol/L in PE and controls | 25(OH)D: PE: 52.2 ± 20.5 nmol/L; Controls: 48.6 ± 20.5 nmol/L (p = 0.3); 25(OH)D deficiency: PE: 38%, Controls: 51.7% (p = 0.1) |
| Halhali, Mexico, 2004 [95] | ↔ 1,25(OH)2D in women before they developed PE | 1,25(OH)2D: median (interquartile range) PE: 31 pg/mL (26–34) NT: 29 pg/mL (24–36) (p = 0.44) |
| Halhali et al., Mexico, 2007 [113] | ↓ 1,25(OH)2D levels in women with PE vs controls | 25(OH)D: PE: 486.7 ± 167.2 nmol/L Controls: 731.1 ± 262.1 nmol/L (p < 0.05) |
| Lechtermann C, et al. Germany, 2014 [85] | ↓ 25(OH)D levels in PE in summer compared to controls, 1,25(OH)2D ↓ only in winter | 25(OH)D: PE: 18.2 ± 17.1; Control: 49.2 ± 29.2 ng/mL, (P < 0.001); 1,25(OH)D: 291 ± 217 vs 612.3 ± 455 pmol/mL (P < 0.05) |
| Mohaghegh et al, Iran, 2015 [89] | ↓ mean 25(OH)D in PE compared to pregnant controls without PE | 25(OH)D: PE: 37.9 ± 33.9 nmol/L Controls: 58.2 ± 38.2 nmol/L (p = 0.001) |
| Powe, USA, 2010 [86] | ↔ women with PE and controls with 25(OH)D < 15.0 nmol/L | Adjusted OR: 1.35 95% CI: 0.40 to 4.50 |
| Robinson et al., USA, 2010 [25] | ↑ EOSPE in women with maternal 25(OH)D levels <=19.6 nmol/L compared to levels >19.6 nmol/L | OR: 3.60 95% CI: 1.71–7.58 (p < 0.001) |
| Schneuer et al., Australia, 2014 [114] | ↔ PE or EOSPE and low 25(OH)D (< 25 nmol/L) | Adjusted OR: all PE: 0.46 95% CI: 0.19–1.10 Adjusted OR: EOSPE: 1.40 95% CI: 0.20 to 9.89 |
| Singla et al, India, 2015 [87] | ↓ mean serum vitamin D in women with PE vs controls | PE: 24.2 ± 12.4 nmol/L Controls: 36.9 ± 16.7 nmol/L; (p = 0.0001) |
| Ullah et al., Bangladesh, 2013 [82] | ↑ PE per 25 nmol/L decrease in 25(OH)D level | Adjusted OR: 1.66 95% CI: 1.05–3.02 |
| Wetta et al., UK, 2013 [96] | ↔ between PE and 25-OH D < 30 ng/mL and <37.4 nmol/L | <30 ng/mL Adjusted OR: 1.1 95% CI: 0.6–2.0 Adjusted OR: 1.4 (<37.4 nmol/L) 95% CI: 0.7–3.0 |
populations had specific risk factors for vitamin D deficiency such as race or seasonal sun exposure. A nested case control study showed an association between EOSPE and vitamin D deficiency after the diagnosis of EOSPE. Serum 25(OH)D was measured at the time of diagnosis of EOSPE (~ 29 weeks of gestation). Controls were matched to cases according to gestational age at diagnosis with EOSPE and race. In patients with EOSPE ($n = 50$), 25(OH)D was significantly lower compared to the controls ($n = 100$) (44.9 vs. 79.9 nmol/L; $p < 0.001$). There was an adjusted odds ratio (aOR) of 3.6 ([95% CI 1.71–7.58], $p < 0.001$) for EOSPE when maternal 25(OH)D was less than or equal to 19.6 nmol/L. There was also a 12-fold increase in odds of diagnosis with EOSPE in African American women, who had the lowest mean 25(OH)D concentration among groups categorized by race [25]. In an Iranian case control study conducted in the fall and winter months, 25(OH)D levels were measured at the time of delivery in 41 pre-eclamptic women, 50 normal women and from their umbilical cord samples immediately after birth. This study found mean 25(OH)D levels to be significantly lower in pre-eclamptic women versus normal women (37.9 ± 33.9 nmol/L vs. 58.2 ± 38.2 nmol/L, respectively, $p = 0.001$). There was a significant relationship between vitamin D levels in pre-eclamptic women with levels in their neonates ($r = 0.901$, $p = 0.0001$) [89].

Two studies of vitamin D in PE cases have evaluated the possible relationship with angiogenic factors. In a small nested case control study that matched cases of severe PE by race and ethnicity to healthy controls, 25(OH)D levels were found to be an independent predictor for severe PE. In women with a 10 nmol/L increase in maternal 25(OH)D, there was a 38% reduction in the odds of severe PE (aOR = 0.62, 95% CI: 0.51–0.76). Women with severe PE had significantly lower levels of PIGF ($p = 0.03$) and VEGF ($p = 0.0007$) and a higher sFLT-1/PIGF ratio ($p = 0.02$) compared to controls. However, there were no independent correlations reported between 25(OH)D levels and these angiogenic markers. A limitation of this study was heterogeneity of parity, a potentially confounding variable, in pre-eclamptic cases (44% multiparous) [15]. A retrospective fully blinded cohort study of 257 pregnant women in an obstetric emergency service in Spain also found no association between sFLT-1/PIGF and 25(OH)D levels in women with PE. However, this study found a greater risk of late-onset PE among women with low 25(OH)D level (<50 nmol/L) (OR 4.6, 95% CI 1.4–15) and increased risk of both early- and late-onset PE when sFLT-1/PIGF ratios were above corresponding cut-points (ORs 58 [95% CI 11–312] and 12 [95% CI 5.0–27], respectively) [90].

There have been a small number of clinical trials studying associations between maternal vitamin D and

| Table 3 Association between vitamin D and pre-eclampsia (PE) in observational studies (Continued) |
|------------------------------------------|-------------------------------------------------|
| Woodham et al., USA, 2011 [15] | ↓ Severe PE in women with 10 nmol/L increase in maternal 25(OH)D level Adjusted OR: 0.62 95% CI: 0.51–0.76 |
| Xu et al., USA, 2014 [53] | ↑ PE in women with vitamin D deficiency (<3.75 nmol/L) OR: 4.4 95% CI: 1.8–10.8 |
| Yu et al., UK, 2012 [115] | ↔ serum vitamin D raw values in PE and controls 25(OH)D levels: Controls: 46.8 nmol/L (27.8–70.0); Early PE: 32.2 nmol/L (22.7–50.4); Late PE: 39.2 nmol/L (22.1–63.0) ($p = 0.231$) |
| Alvarez-Fernandez et al., Spain, 2014 [90] | ↑ PE in women with 25(OH)D levels <50 nmol/L compared to levels >50 nmol/L after 20 weeks of gestation OR: 4.6 95% CI:1.4–15 ($p = 0.010$) |
| Scholl et al., USA, 2013 [78] | ↑ PE in women with 25(OH)D < 49.9 nmol/L and hyperparathyroidism Adjusted OR: 2.86 95% CI: 1.28–6.41 |
| Burris et al., USA, 2014 [94] | ↔ PE and 25(OH)D levels compared at each 25 nmol/L increase in 25 (OH)D Adjusted OR: 1.14 95% CI: 0.77–1.67 |
| Haugen et al., Norway, 2000 [77] | ↓ PE in women taking 10–15 mcg/d as compared with no supplements Adjusted OR: 0.73 95% CI: 0.58–0.92 |
| Shand et al, Canada, 2010 [37] | ↔ PE and 25(OH)D levels <37.5 nmol/L Adjusted OR: 0.91 95% CI: 0.31–2.62 |
| Wei et al., Canada 2012 [60] | ↔ PE and 25(OH)D < 50 nmol/L Adjusted OR: 1.24 95% CI: 0.58–2.67 ($p = 0.58$) |
| Wei, Canada, 2013 [14] | ↑ PE and women with ↓ PIGF levels and maternal 25(OH)D < 50 nmol/L Adjusted OR: 2.97 95% CI: 1.23–7.20 |
| Zhou, China, 2014 [116] | ↔ PE and 25(OH)D levels 25(OH)D levels Group A (n = 13): 41.4 ± 6.5 nmol/L; Group B (n = 36): 62.1 ± 7.0 nmol/L; group C (n = 23): 89.6 ± 13.0 nmol/L; ($p = 0.000$) |
hypertensive disorders in pregnancy (Table 4). In a 50-year-old controlled trial of 5644 women, Olsen & Secher assessed the preventive effect of a multi-vitamin mineral supplement, which included iron, calcium, iodine, manganese, copper, vitamin B complex, vitamin C, and 260 mg/day of calcium and halibut liver oil containing 2500 IU/g vitamin D per day. Among women who were given supplementation from week 20 of gestation onwards, there was a 31.5% reduction in the odds of PE (p < 0.005). No significant effect was observed in the odds of developing gestational hypertension [91]. Of note, omega-3 fatty acids found along with vitamin D in cod liver oil are likely to play an independent role in preventing PE [92, 93].

**Evidence that suggests no association between maternal vitamin D deficiency and PE**

While the preceding studies support a link between vitamin D deficiency during pregnancy and risk of PE, some studies present conflicting evidence (Tables 2 and 3). Most of these studies were observational, and measured maternal vitamin D concentration before the diagnosis of PE as opposed to measuring at the time of diagnosis or delivery. A 2010 prospective cohort study did not find an association between low serum 25(OH)D levels (<37.5 nmol/L) in the first half of pregnancy and the development of PE (aOR = 0.91 CI: 0.31–2.62) or gestational hypertension (aOR = 1.55 CI: 0.58–4.17) in women who were at high-risk for PE after controlling for smoking and parity. This study used high-risk women, both nulliparous and multiparous, who did not develop PE as controls [37]. Another cohort study in 2014 found no association between low plasma 25(OH)D concentration (<25 nmol/L) and PE in women at 16.4–36.9 weeks of gestation (aOR = 0.60 95% CI:0.14–2.56). Rather, investigators found for every 25 nmol/L increase in 25(OH)D, the aOR for PE was 1.14 (95% CI: 0.77–1.67) [94].

In 2012, Wei et al. retrospectively analyzed vitamin D status and the risk of PE in 697 nulliparous women with singleton pregnancies in a randomized, placebo-controlled trial of Vitamin C and E supplementation for the prevention of PE. After controlling for smoking, the study showed that in the first trimester (mean 11 weeks), vitamin D deficiency was not significantly associated with an increased risk of PE (aOR = 1.24 95% CI: 0.58–2.67; p = 0.58) [60]. In a 2013 follow-up study of women from the same cohort, Wei et al. found that PIGF level was inversely associated with PE (p < 0.05) [13]. In a multivariate logistic model to control for PIGF there was an aOR of 2.97 (95% CI: 1.23–7.20) for PE among women with 25(OH)D levels less than 50 nmol/l. This was only an 8.3% reduction in the risk for PE compared to when PIGF levels were not considered. There was no statistical evidence of interaction between PIGF and vitamin D (p = 0.54) [14].

In 2004, a longitudinal case control study did not find altered circulating 1,25(OH)2D during mid-pregnancy in those who developed PE compared to healthy, normotensive women [95]. In 2010, Powe et al. suggested that earlier studies have measured total 25(OH)D as a vitamin D/Vitamin D Binding Protein (VDP) complex, and not the free vitamin. Therefore, Powe et al. conducted a study measuring levels of both total and free 25(OH)D in the first trimester of PE and normotensive pregnancies. They found total and free 25(OH)D levels were similar in cases and controls (68.4 ± 4.7 nmol/L versus 71.9 ± 2.0 nmol/L, p = 0.435). There was no association between 25(OH)D levels <15.0 nmol/L and risk of PE (aOR = 1.35 95% CI: 0.40 to 4.50) [86]. In a nested case control study of women with singleton pregnancies, 100 pregnant women with PE were matched to 200 healthy controls who delivered at 39–40 weeks. 25(OH)D levels were assessed from stored blood samples drawn between 15 and 21 weeks gestation for multiple marker screening. After adjusting for covariates, vitamin D insufficiency and deficiency were not significantly associated with PE (aOR = 1.1 95% CI: 0.6–2.0; aOR = 1.4 95% CI: 0.7–3.0, respectively) [96].

In a cross-sectional study of 466 pregnant women attending an outpatient clinic in Spain, serum 25(OH)D was measured between 11 and 14 weeks of pregnancy. No associations were found between maternal 25(OH)D levels less than 49.9 nmol/L or 25(OH)D between 49.9 and 74.9 nmol/L in cases of PE and gestational hypertension identified during follow-up [97].

In 2000, a double-blind, randomized, placebo-controlled trial evaluated the effects of 2.7 g fish oil supplementation given prophylactically from 20 weeks until

---

| Study Design | Subjects | Intervention | Key Findings | Results |
|-------------|----------|--------------|--------------|---------|
| Olsen and Secher, Denmark, 1990 [91] | Randomized controlled clinical trial | 5644 pregnant women | 2500 IU vitamin D supplement versus no supplement at week 20 of pregnancy | ↓ PE | 31.5% reduction in the odds (p < 0.005) |
| Olsen et al., Europe, 2000 [98] | Randomized placebo controlled clinical trial | 386 women who previously experienced PIH | 2.7 g n-3 fatty acids/day given from 33 weeks until delivery vs olive oil placebo | ↔ PIH recurrence risk | OR = 0.98 95% CI: 0.63–1.53 |

---

**Table 4** Association of vitamin D supplementation and pregnancy-induced hypertension (PIH) outcomes in clinical trials
delivery in women who had previously experienced Pre-
nancy Induced Hypertension (PIH) (n = 386). Supple-
mation with fish oil did not affect the recurrence risk for
PIH in the prophylactic trial (OR = 0.98 CI: 0.63–1.53). Vita-
m D concentrations were not reported [98].

**Discussion**

Observational studies evaluating the association between
vitamin D and PE have shown inconsistent results and
must be interpreted cautiously. This may be a result of
issues with study design and methodology, including
lack of adjustment of key confounding variables and
methods of measuring vitamin D levels.

Study findings must be interpreted in the context of
study design. Most previous studies were based on
cohort studies that collected clinical data and stored blood
in repositories at regular intervals. Many researchers uti-
lized a case-control study design within these cohorts, or
performed cross-sectional studies. Residual confounding
and differences between groups may explain the associ-
ation between vitamin D deficiency and PE.

Most studies controlled for maternal age, body mass
index, season, and gestational trimester at sample collec-
tion. In addition, some studies also controlled for smoking
[14, 37]. Smoking has consistently been shown to reduce
the risk of PE and gestational hypertension [99, 100]. This
could be due to an association between smoking and
lower circulating concentrations of anti-angiogenic pro-
tiens and higher concentration of pro-angiogenic proteins
[101]. Smoking has also been linked to lower vitamin D
concentrations [37]. Smoking may be an important con-
founder and should be considered in studies linking vita-
m.D to PE. The pathophysiology of PE may also vary by
parity [102]. Wetta et al., [96], Shand et al., [37] and Bod-
nar et al., [18] have controlled for parity in their studies.

Individuals receive the majority of their vitamin D from
sunlight, linking seasonality to the development of PE.
Seasonality is also considered a confounder, particularly in
studies related to causal effects of vitamin D on PE. Se-
asonal and latitudinal variation has an effect on vitamin D3
production in the skin [103]. According to a study by
Magnus and Eskild [104], in Norway, mothers of children
born in August had the lowest risk of PE. Risk in this
study was highest in the winter months (for December,
aOR: 1.26, 95% CI: 1.20–1.31) [104]. Similarly, Bodnar
et al. [18] found that the incidence PE among white women
in the United States was highest in the winter, when pro-
duction of cutaneous vitamin D3 is limited in temperate
zones and serum 25(OH)D are at their lowest levels. How-
ever, despite this known association, not all studies look-
ing at PE as an outcome report information on seasonal,
latitudinal variation, sun exposure and lifestyle difference-
s—all of which may differentially expose individuals to
sunlight in the sample population.

Maternal dietary intake of vitamin D from foods or
supplements may also vary. Oily fish and cod liver oil
(n-3 fatty acids) are a rich source of vitamin D. In the
Norwegian diet, intake of vitamin D is correlated with
intake of long chain n-3 fatty acids [77]. The use of cod
liver oil as a food supplement in some diets presents a
challenge in determining an isolated effect of vitamin D
supplementation. This was noted by Haugen et al. [77],
who were unable to control for the intake of fatty acids
in their analysis. In their secondary analysis with intake
of long chain n-3 fatty acids and vitamin D, a weaker
association with the incidence of PE was observed [77].

Although randomized clinical trials (RCTs) offer the op-
portunity to design studies with power to provide defini-
tive evidence, few have been performed in this field. RCTs
reviewed in this article were not able to study vitamin D
supplementation independently of calcium and/or other
multivitamin/micronutrient supplementation. In a
Cochrane review of Vitamin D supplementation for
women during pregnancy, women who received vitamin
D and calcium supplementation had a lower risk of pre-
eclampsia than those not receiving any intervention (RR
0.51; 95% CI 0.32 to 0.80; three trials, 1114 women, mod-
erate quality), yet an increased risk for preterm birth
(RR = 1.57; 95% CI: 1.02–2.43; three studies, 798 women,
moderate quality). In trials with an intervention of vitamin
D without calcium, women who received vitamin D sup-
plements had a statistically nonsignificant lower risk of
pre-eclampsia than those receiving no intervention or pla-
cebo (8.9% versus 15.5%; risk ratio (RR) 0.52; 95% CI 0.25
to 1.05; low quality) with no adverse outcomes [105]. The
role of fish oils in PE remains uncertain and similarly
poses a challenge in determining an isolated effect of vita-
m D supplementation, unless studies are designed such
that they consider this. In the RCTs reviewed, no conclu-
sions can be made regarding the independent effects of
vitamin D in preventing or treating PE.

Studies must also be interpreted according to how vita-
m in D exposure is defined and measured. “The free hor-
mone hypothesis” postulates that hormones that are free
from their binding proteins may enter cells to perform
biological functions [106]. During pregnancy, VDBP in-
creases by 2-fold [86]. Future investigations should con-
sider concurrently measuring VDBP levels and calculated
free vitamin D levels when considering the role of vitamin
D in PE [18]. Additionally, investigators should attempt to
assess preconception and early pregnancy dietary intake,
sun exposure or baseline vitamin D status.

Studies that find a role early in pregnancy, before the
clinical onset of PE, suggest that vitamin D may play a
role in the modulation of a pro-inflammatory response
or regulation of angiogenic factors. It is possible that
biomarkers for PE, such as angiogenic factors VEGF and
PIGF, may serve as mediators in the pathway linking
vitamin D metabolites to PE. Despite evidence that low vitamin D levels increase risk for PE early in pregnancy, very few studies have tried to relate this effect with the regulation of angiogenic or anti-angiogenic factors. Although current evidence supports an association between angiogenic factors and PE, these studies have not found an association between vitamin D levels and angiogenic factors [14, 15]. Studies with longitudinal study design carefully controlling for temporal sequences of changes in vitamin D levels in women with PE are needed to identify the role of vitamin D and any potential mediators in the pathway linking vitamin D to PE.

There are important clinical considerations that necessitate the need for further research on this topic. There is limited data on the most efficacious dose of vitamin D to prevent pre-eclampsia while avoiding toxicity. The doses of vitamin D supplements in the studies reviewed ranged from 400 to 2500 IU daily [91]. These studies reported no major adverse effects of supplementation at these doses [107–109]. Recently, participants in the Vitamin D for Antenatal Asthma (VDAART) randomized double-blind placebo controlled trial took a daily dose of 4000 IU vitamin D supplementation plus a multivitamin with 400 IU vitamin D or placebo (placebo pill plus a multi-vitamin with 400 IU vitamin D daily) to assess the effect of vitamin D supplementation on the frequency of PE among pregnant women with a high risk for atopic disease [110].

The investigation by Haugen et al. suggests a potential for a role for the frequency and timing of vitamin D supplementation and risk for PE, given that the total intake greater than 800 IU/day did not reduce risk. However, Haugen et al. found that women who took supplements at all three points of pregnancy (before pregnancy, early pregnancy and in late pregnancy) were at a lower risk for PE compared with women who took supplements in only early or late pregnancy or did not take any supplements [77]. In the VDAART, frequency of PE among pregnant women with a high risk for atopic disease was not lower when a supplementation of 4400 IU vitamin D daily was given in early pregnancy (10–18 weeks). However, women with a serum vitamin D status of ≥75 nmol/L that was maintained from enrollment through late pregnancy had a significantly lower risk of PE versus women who had <75 nmol/L (P = 0.04). But this vitamin D level was maintained in only 74% of pregnancies in the supplementation group by weeks 32 to 38 of gestation, suggesting that supplementation at even earlier time-points or before pregnancy may be necessary to maintain sufficient vitamin D levels that are protective against PE. This was further supported by peripheral blood gene expression patterns relating to immune and inflammatory processes identified as early as the 10th week of pregnancy that were unique in women who went on to develop PE [110].

Additionally, early-onset and late-onset PE have unique clinical features, biomarkers and prognoses that may guide clinical dose recommendations. Studies reported varying degrees of risk for clinical subtypes of PE among women with low vitamin D levels [79, 90]. In order to guide the clinical recommendations, investigators must use a standard set of definitions for the disease and clinical subtypes in future research. In the current literature, the definition of PE was not consistent across studies, limiting our ability to draw generalizations. For example, clinical cutoffs for proteinuria varied slightly among studies [86, 87]. Replication of findings using a uniform set of definitions for PE and clinical subtypes can inform the use of vitamin D supplementation for the prevention of PE.

Robinson et al. [25] suggest that vitamin D deficiency may be a factor in the disproportionate incidence of adverse pregnancy outcomes in African American women since this group had the lowest vitamin D levels among the populations they studied. While some studies have been able to capture an adequate representation of African American women [96], there is a need for further research on populations with very low vitamin D levels to understand this observation and identify factors that predispose high-risk groups to PE and its more threatening clinical subtypes.

Despite the clear association of serum deficiency with PE, a better understanding of the variable impact of supplementation is needed to identify potential of genetic and environmental interactions, as well as pre-conception data to identify the critical time window for therapeutic potential of vitamin D, if any.

Conclusion
There is consistent evidence of an association between low vitamin D concentrations and adverse PIH outcomes. Results from vitamin D supplementation during pregnancy did not show a statistically significant independent effect of vitamin D on the risk of PE and PIH.

At this time, our understanding of an ideal supplementation dose of vitamin D to reduce PIH remains incomplete. Future studies should include follow up from the pre-conception period until delivery to elucidate the mechanisms and interactions which drive vitamin D status, response, and onset of PE to inform population-specific dose recommendations.

Additional file

Additional file 1: PRISMA Checklist. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: PRISMA. (DOC 63 kb)

Abbreviations
1,25(OH)2D: 1,25-dihydroxyvitamin D; 25(OH)D: 25-hydroxyvitamin D; EOSPE: Early Onset Severe Pre-eclampsia; HELLP: Hemolytic anemia, Elevated liver enzymes, Low Platelets; IL-10: Interleukin-10; IUGR: Intrauterine Growth
Acknowledgements

The authors would like to thank Dr. Julia Finkelstein, Assistant Professor of Epidemiology and Nutrition for her essential comments during the drafting of this review. We are grateful to the Division of Nutritional Sciences, Cornell University and the Hunter R. Rawlings III Cornell Presidential Research Scholars program for academic support to Juhi Purswani as an undergraduate research scholar.

Funding

No funds were used for this student project.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

JP and PG wrote the initial draft of the manuscript. PD helped revise the manuscript and contributed to interpretation of the included studies. HL consulted on review methodology, contributed to writing, and interpretation of results. SM and AK contributed to conception and design, acquisition of data, analysis and interpretation of data. All authors have read and approved the final version of this manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

SM has equity interest in a startup focusing on point-of-care diagnostic platforms for nutritional status that were developed as part of their research program as a faculty member at Cornell University.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Division of Nutritional Sciences, Cornell University, 314 Savage Hall, Ithaca, NY 14853, USA. 2Weill-Cornell Medical College, New York, NY, USA. 3St. John’s Research Institute, Bangalore, Karnataka, India.

Received: 18 September 2015 Accepted: 3 July 2017 Published online: 15 July 2017

References

1. World Health Organization. Fact Sheet - Maternal Mortality. http://www.who.int/mediacentre/factsheets/fs348/en/. Accessed 23 July 2016.
2. Peters RM, Flack JM. Hypertensive disorders of pregnancy. J Obstet Gynecol Neonatal Nurs. 2004;33(2):209–20.
3. Roberts JM, Baik JL, Bodnar LM, Bellizan JM, Bergel E, Martinez A. Nutrient involvement in preeclampsia. J Nutr. 2003;133(5 Suppl 2):1828–925.
4. Zhang J, Zeisler J, Hatch MC, Berkowitz G. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev. 1997;19(2):218–32.
5. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(5):130–7.
6. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. 2001;97(4):533–8.
7. Sibai BM. Diagnosis, prevention, and management of preeclampsia. Obstet Gynecol. 2005;105(2):402–2.
8. Srinivas SK, Eddow AG, Nef MP, Sammel MD, Andrela CM, Elovitz MA. Rethinking IUGR in preeclampsia: independent or dependent of maternal hypertension? J Perinatol: official journal of the California Perinatal Association. 2009;29(10):680–4.
9. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69(1):1–7.
10. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544 e541–12.
11. Irgens HU, Reisaeter L, Irgens LM. Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323(7323):1213–7.
12. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,200 births. Lancet. 2001;357(9273):2002–6.
13. Redman CW. Immunological aspects of pre-eclampsia. Baillieres Clin Obstet Gynecol. 1992;6(3):601–15.
14. Wei SQ, Audibert F, Luo ZC, Niyt AM, Masse B, Julien P, Fraser WD, Group MS. Maternal plasma 25-hydroxyvitamin D levels, angiogenic factors, and preeclampsia. Am J Obstet Gynecol. 2011;205(3):391.e1–6.
15. Woodham PC, Brittain JE, Baker AM, Long DI, Hæri S, Camargo CA Jr, Boggess KA, Stuebe AM. Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia. Hypertension. 2011;58(6):1120–5.
16. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30(Suppl A):S52–7.
17. Young BC, Levine RJ, Kanarananchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–92.
18. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab. 2007;92(9):3517–22.
19. Cardus A, Parisi E, Gallego C, Aldesa M, Fernandez E, Valdivielso JM. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006;69(9):1377–84.
20. Evans KN, Bullmer JN, Kilby MD, Hewison M. Vitamin D and placental-decidual function. J Soc Gynecol Investig. 2004;11(5):263–71.
21. Fischer D, Schroer A, Ludders D, Cordes T, Bucker B, Reichrath J. Vitamin D and preeclampsia: a re-evaluation. Placenta. 2009;30(Suppl A):S8.
22. Halhali A, Tovar AR, Torres N, Bourges H, Garabedian M, Larrea F. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2001;25(1):1–7.
23. Marya RK, Rathee S, Manrow M. Effect of calcium and vitamin D supplementation on toxaemia of pregnancy. Gynecol Obstet Investig. 1987;24(1):38–42.
24. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, Toprak A, Yazici MS. vitamin D, Sancak S, Deynali O, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94(10):4023–30.
25. Robinson CJ, Alainis MC, Wagner CL, Hollis BW, Johnson DD. Plasma 25-hydroxyvitamin D levels in early-onset severe preeclampsia. Am J Obstet Gynecol. 2010;203(4):366 e361–6.
26. Hollis BW, Wagner CL. Assessment of dietary vitamin D requirements during pregnancy and lactation. Am J Clin Nutr. 2004;79(5):717–26.
27. IOM (Institute of Medicine): Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC; 2011.
28. Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, Arden NK, Godfrey KM, Cooper C, Princess Anne Hospital Study G. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet. 2006;367(9504):36–43.
29. Weiler H, Fitzpatrick-Wong S, Veitch R, Kovacs H, Schellenberg J, McCloy U, Wintour P, Purswani et al. BMC Pregnancy and Childbirth (2017) 17:231
33. van der Meer IM, Karamali NS, Boeke AJ, Lips P, Middelkoop B, Verhoeven I, Wuister JD. High prevalence of vitamin D deficiency in pregnant non-western women in The Hague, Netherlands. Am J Clin Nutr. 2006;84(2):350–3. quiz 468–359.

34. Datta S, Alfarah M, Davies DP, Dunstan F, Woodhead S, Evans J, Richards B. Vitamin D deficiency in pregnant women from a non-European ethnic minority population—an interventional study. BJOG. 2009;10(8):905–8.

35. Finch PJ, Ang L, Colston KW, Nisbet J, Maxwell JD. Blunted seasonal variation in serum 25-hydroxy vitamin D and increased risk of osteomalacia in vegetarians. Lancet. 1986;2(8465):59–9.

36. Dör D, Allen LH. Vitamin D inadequacy in pregnancy: biology, outcomes, and interventions. Nutr Rev. 2010;68(8):465–72.

37. Shand AW, Nassar N, Von Dadelszen P, Innis SM, Green TJ. Maternal vitamin D status and pregnancy outcome in a group at high risk for pre-eclampsia. BJOG. 2010;117(11):1593–8.

38. Skull SA, Ngeow JY, Biggs BA, Street A, Ebeling PR. Vitamin D deficiency is common and unrecognized among recently arrived adult immigrants from the horn of Africa. Intern Med J. 2003;33(1):247–51.

39. Hobbis RD, Habib Z, Altomali D, Li L, Panahi N, Blocli F, Rao DS. Severe vitamin D deficiency in Arab-American women living in Dearborn, Michigan. Endocr Pract. 2009;15(1):35–40.

40. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Dougherty C, Gunter EW, Bowman BA. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and nutrition examination survey, 1988–1994. Am J Clin Nutr. 2002;76(1):187–92.

41. Ardawi MS, Nasrat HA, BA'Aqueel HS. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study. Eur J Endocrinol. 1997;137(4):402–10.

42. Sanchez PA, Idrisa A, Bobzom DN, Airede A, Hollis BW, Liston DE, Jones DD, et al. 1,25-dihydroxyvitamin D3 receptor: changes in serum intact parathyroid hormone and 1,25-dihydroxyvitamin D. J Obstet Gynecol. 1997;17(1 Pt 1):214–7.

43. Gray TK, Lester GE, Lorenz RS. Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy. Science. 1979;204(4399):1311–2.

44. Weisman Y, Harel E, Edelstein S, David M, Spirer Z, Golander A. 1 alpha, 25–hydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3 receptor cytoplasmic cell dysfunction induced by sera from women with preeclampsia or conditioned media from hypoxic placenta. Placenta. One. 2014;6(9):e98527.

45. Wei SQ, Audibert F, Hidirogoulo N, Sarafin K, Julien P, Wu Y, Luo ZC, Fraser WD. Longitudinal vitamin D status in pregnancy and the risk of pre-eclampsia. BJOG. 2012;119(7):852–9.

46. Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta. 2008;29(9):763–71.

47. Langer B, Grima M, Coquard C, Bader AM, Schlaeger G, Imbs JM. Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia. Obstet Gynecol. 1998;91(2):196–202.

48. Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA. Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin-1 converting enzyme deletion/deletion genotype. Brazilian J Med Biol Res. 2007;40(4):583–90.

49. Faulkner JL, Aarnal LM, Cornellus DC, Cunningham MW, Ibrahim T, Heep A, Campbell N, Usry N, Wallace K, Herse F, et al. Vitamin D supplementation reduces some AT1A-IA-induced downstream targets implicated in preeclampsia including hypertension. Am J Physiol Regul Integr Comp Physiol. 2017;312(1):R125–31.

50. Li YC, Qiao G, Ussokovich M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89(1–3):387–92.

51. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive women. Hypertension. 1997;30(3):1289–94.

52. Rennick LM, Nicholson JP, Laragh JH. Calcium metabolism in essential hypertension: relationship to altered renin system activity. Fed Proc. 1986;45(12):2729–35.

53. Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int. 1987;41(2):112–4.

54. Walters MR, Wicker DC, Riggle PC. 1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. J Mol Cell Cardiol. 1986;18(1):67–72.

55. Stumpf WE, O'Brien LP. 1,25 (OH)2 vitamin D3 sites of action in the brain. J Endocrinol. 1989;125(3):R125–31.

56. Merchant SJ, Naramiya H, Zhang Y, Guibert LJ, Davidge ST. The effects of preeclampsia and oxygen environment on endothelial release of matrix metalloproteinase-2. Hypertension. 2004;43(1):47–60.

57. Sankaranlingam S, Arenas IA, Lalu MW, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med. 2006;8(3):1–20.

58. Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, Hausteller MR, Rautenberg EW, Ritz E. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies of understanding the molecular basis of vascular dysfunction. Expert Rev Mol Med. 2006;8(3):1–20.

59. Haugen M, Brantsaeter AL, Trogstad L, Alexander J, Roth C, Magnus P, Meltzer HM. Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. Epidemiology. 2009;20(5):720–6.

60. Scholl TO, Chen X, Stein TP, Vitamin D, secondary hyperparathyroidism, and preeclampsia. Am J Clin Nutr. 2013;98(3):787–93.
97. Fernandez-Alonso AM, Dionis-Sanchez EC, Chedraui P, Gonzalez-Salmeron
96. Wetta LA, Biggio JR, Cliver S, Abramovici A, Barnes SJ, Tita AT. Is midtrimester
95. Halhali A, Villa AR, Madrazo E, Soria MC, Mercado E, Diaz L, Avila E,
93. Williams MA, Zingheim RW, King IB, Zebelman AM. Omega-3 fatty acids in
92. Jensen CL. Effects of n-3 fatty acids during pregnancy and lactation. Am J
91. Olsen SF, Secher NJ. A possible preventive effect of low-dose fish oil on
89. August P, Marcaccio B, Gertner JM, Druzin ML, Resnick LM, Laragh JH.
88. Singla R, Gurung P, Aggarwal N, Dutta U, Kochhar R. Relationship between
87. Singla R, Gurung P, Aggarwal N, Dutta U, Kochhar R. Relationship between
86. Powe CE, Seely EW, Rana S, Bhan I, Ecker J, Karumanchi SA, Thadhani R. First
85. Schmidt M, Grasemann C. Maternal vitamin D status in preeclampsia:
84. Abedi P, Mohaghegh Z, Afshary P, Latifi M. The relationship of serum
83. Pena HR, de Lima MC, Brandt KG, de Antunes MM, da Silva GA. Influence of
82. Purswani BM, Jain V, Khan R, Leibowitz J, Garg A, Vaidya P, Shaw A, Patel B,
81. Aibed P, Mohaghegh Z, Afshary P, Latifi M. The relationship of serum vitamin
80. Halabi D, Diaz L, Avila E, Gorodischer G, Labrador M, Padilla MJ, Zwickl K, de
79. Bodnar LM, Simhan HN, Catov JM, Roberts JM, Platt RW, Diesel JC, Klebanoff
78. Edwards JW, Camargo CA Jr, Gillman MW. Vitamin D status and hypertensive
disorders in pregnancy. Ann Epidemiol. 2014;24(5):399–405.
77. Weston J, Sallinen V, Aro A. Maternal serum 1,25-dihydroxyvitamin D levels and pregnancy outcomes: a prospective observational study in southern China. Eur J Clin Nutr. 2014;68(9):925–30.
76. Wetta LA, Biggio JR, Cliver S, Abravomovic A, Barnes SJ, Tita AT. Is mid trimester vitamin D status associated with spontaneous preterm birth and preeclampsia? Am J Perinatol. 2014;31(6):541–6.
75. Fernandez-Alonso AM, Dionsis-Sanchez EC, Chedraui P, Gonzalez-Salmeron MD, Perez-Lopez FR, Spanish Vitamin D, Women’s Health Research G. First trimester maternal serum 25-hydroxyvitamin D(3) status and pregnancy outcome. Int J Gynecol Obstet. 2012;116(1):6–9.
74. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Giud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish oil trials in pregnancy (FOTIP) team. BJOG. 2000;107(3):382–95.
73. Marcoux S, Brisson J, Fabia J. The effect of cigarette smoking on the risk of preeclampsia and gestational hypertension. Am J Epidemiol. 1989;130(5):950–7.
72. England L, Zhang J. Smoking and risk of preeclampsia: a systematic review. Front Biosci. 2007;12:2471–83.
71. Jeyabalan A, Powers RW, Durica AR, Harper GF, Roberts JM, Ness RB. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am J Hypertens. 2008;21(8):943–7.
70. Badrda LT, Amarino ZO. Pre-eclampsia: is it a different disease in primiparous and multiparous women? Arch Gynecol Obstet. 2005;273(1):26–31.
69. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67(2):373–8.
68. Magnus P, Eskild A. Seasonal variation in the occurrence of pre-eclampsia. BJOG. 2001;108(11):116–9.
67. De-Regil LM, Palacios C, Ansay A, Kulier R, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy (Version 2). Cochrane Database Syst Rev. 2012;2:1–50.
66. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989;10(3):232–74.
65. March KM, Chen NN, Karakouchuk CD, Shand AW, Innis SM, von Dadelszen P, Barr SL, Lyon MR, Whiting SJ, Weiler HA, et al. Maternal vitamin D(3) supplementation at 50 mug/d protects against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized controlled trial of 3 doses of vitamin D beginning in gestation and continued in lactation. Am J Clin Nutr. 2015;102(2):402–10.
64. Shkolka M, Iranmanesh MR. Vitamin D requirement in pregnancy to prevent deficiency in neonates: a randomised trial. Sinaq Med J. 2013;54(5):285–8.
63. Boucher BJ. The 2010 recommendations of the American Institute of Medicine for daily intakes of vitamin D. Public Health Nutr. 2011;14(4):740.
62. Mizakian H, Litonjua AA, McInturf TF, O’Connor G, Lee-Parritz A, Iverson R, Macones G, Strunk RC, Bacharier LB, Zeiger R, et al. Early pregnancy vitamin D status and risk of preeclampsia. J Clin Invest. 2016;126(12):4702–15.
61. Anderson CM, Ralph JL, Johnson L, Scheetz A, Wright ML, Taylor JY, Ohm JE, Uthus E. First trimester vitamin D status and placental epigenomics in preeclampsia among Northern Plains primiparas. Life Sci. 2015;129:10–5.
60. Gidlof S, Silva AT, Gustafsson S, Lindqvist PG. Vitamin D and the risk of preeclampsia—a nested case-control study. Acta Obstet Gynecol Scand. 2015;94(8):904–8.
59. Halabi D, Diaz L, Avila E, Ariza AC, Garabedian M, Larrea F. Decreased fractional urinary calcium excretion and serum 1,25-dihydroxyvitamin D and IGF-I levels in preeclampsia. J Steroid Biochem Mol Biol. 2007;103(3–5):803–6.
58. Schneuer FJ, Roberts CL, Guilbert C, Simpson JM, Alpert CS, Kambali AS, Tasevski V, Ashton AW, Morris JM, Nassar N. Effects of maternal serum 25-hydroxyvitamin D concentrations in the first trimester on subsequent pregnancy outcomes in an Australian population. Am J Clin Nutr. 2014;99(2):287–95.
57. Yu CK, Erd R, Skyfta E, Akolekar R, Nicolaides KH. Maternal vitamin D levels at 11–13 weeks of gestation in preeclampsia. J Hum Hypertens. 2013;27(2):115–8.
56. Zhou J, Su L, Liu M, Liu Y, Cao X, Wang Z, Xiao H. Associations between 25-hydroxyvitamin D levels and pregnancy outcomes: a prospective observational study in southern China. Eur J Clin Nutr. 2014;68(9):925–30.